How Syner-G BioPharma Facilitated Regulatory Submissions for a Major U.S. Biopharmaceutical Company to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)
About The client is a clinical-stage biotechnology company focused on the phase III development of an anti-interleukin-6 monoclonal antibody therapeutic…
About The client is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat psychiatric and neurological…